Introduction

▼
Blood platelets reveal remarkable parallels to the brain. Platelets are the main source of serotonin and a dysfunction of the serotonergic system is implicated in depression [ 1 ] . Platelets also express amyloid precursor protein (APP) and contain beta-amyloid (Aβ), which aggregates to amyloid plaques in Alzheimer's disease (AD). Furthermore, platelets contain growth factors such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and since both diseases are associated with infl ammation, the activation of platelets and the release of NGF or BDNF may play a potent role. The neurotransmitter serotonin is produced by neurons of the dorsal raphe nucleus and is involved in the regulation of, e. g., mood and cognition [ 2 ] . In the blood, platelets are the main source of serotonin and platelets express diff erent serotonin receptors and the serotonin transporter (SERT) [ 3 , 4 ] . SERT on platelets infl uences the plasma serotonin levels and the number of SERTs per platelet is sensitive to selective serot-BDNF release from platelets [ 14 , 15 ] . Also in stressed rodents the administration of BDNF has been shown to evoke an antidepressant-like eff ect [ 16 ] . The secretion of platelet content requires complex processes, including the formation of prostaglandins that can be abolished by anti-infl ammatory drugs with cyclooxygenase (COX)-inhibitory properties [ 17 ] . So far, the impact of antidepressants and anti-infl ammatory drugs on NGF and BDNF release from platelets is unknown and partly not consistent in the literature. Therefore, the present study aims to investigate the eff ects of anti-infl ammatory drugs (ibuprofen and indomethacin) and antidepressants (citalopram, paroxetine and sertraline) on NGF and BDNF release from rat platelets. We will investigate the eff ects of calcium on the release in a time-dependent manner.
Materials and Methods
▼
Blood collection and platelet isolation and treatment
Platelets were isolated as reported previously [ 18 ] . In total 24 adult Sprague-Dawley rats were used. They were anaesthetized with a high dose of thiopental (Sandoz, Kundl, Austria) and blood was drawn directly from the heart by using a butterfl y blood collection system (Becton Dickinson, Schwechat, Austria). The blood was collected in EDTA tubes (Sarstedt, Wr. Neudorf, Austria) and centrifuged at 250 g for 15 min to obtain plateletrich plasma (PRP). 500 nM prostaglandin-I2 sodium salt (PGI 2 , prostacyclin-sodium salt, Sigma, Vienna, Austria) was added to prevent platelet activation during processing. Platelets were separated from PRP by centrifugation at 2 300 g for 10 min and washed in calcium-free Tyrode buff er (136 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.42 mM NaH 2 PO 4 , 1 mM MgSO 4 , 5 mM glucose, pH 6.5). Washed platelets were centrifuged at 2 300 g for 10 min and were fi nally resuspended in 1 mL Tyrode buff er (adjusted to pH 7.4). All centrifugation steps were performed at room temperature. Freshly isolated platelets (1 × 10 8 ) were incubated with 0.3 μM citalopram (Sigma) or 0.3 μM ibuprofen (Sigma) or 0.3 μM indomethacin (Sigma) or 0.3 μM paroxetine (Smith Kline, Vienna, Austria) or 0.3 μM sertraline (Pfi zer, Vienna, Austria) (fi nal concentration) at 37 °C for 10 min or 60 min in Tyrode buff er (pH 7.4). In addition, platelets were incubated with or without 2 mM calcium chloride (Ca 2+ ). To stop the release 1.7 mM EDTA (fi nal concentration) were added and samples were centrifuged at 2 300 g for 10 min. The supernatant was collected and frozen at − 80 °C until analysis.
Serotonin analysis by HPLC
Serotonin was measured by high-performance liquid chromatography (HPLC) and electrochemical detection as reported previously [ 19 ] . Samples were thawed and 20 μL supernatant were injected into the HPLC. The samples were separated on a reversed-phase C18 Nucleosil column (Bartelt, Graz, Austria) at a fl ow rate of 1 mL/min using the following mobile phase: 0.05 M trichloric acid (Merck, Darmstadt, Germany), 0.26 mM EDTA (Merck), 1.36 mM NaCl (Roth, Karlsruhe, Germany), 1.81 mM heptanesulfonic acid (Sigma) and 15 % acetonitrile (BDH Prolabo, Vienna, Austria) in HPLC water. Detection was performed with an electrochemical detector (Antec II, Leyden, Netherlands) at + 0.55 V and 30 °C. All unknown samples were correlated to external standards of serotonin (Sigma). Analysis was performed by measuring peak heights at the respective retention times of the substances (serotonin 7.8 min).
NGF and BDNF immunoassays
BDNF and NGF levels were measured using commercial enzymelinked immuno-sorbent assay (ELISA) kits (Promega, Mannheim, Germany). Detection of BDNF and NGF was performed as described by the manufacturer. Briefl y, 100 μL standards or samples were added to coated wells and incubated for 6 h at room temperature. After washing, the detection antibodies were added and samples were incubated over night at 4 °C. Wells were washed again and incubated with horseradish peroxidase conjugate for 2.5 h. After washing, TMB one solution was added. After 10 min the reaction was stopped and the absorbance was measured at 450 nm in a Zenyth 3 100 ELISA reader.
Data and statistical analysis
All data obtained from NGF, BDNF and serotonin release were analyzed with a one-way ANOVA and a subsequent Fisher LSD posthoc test, where p < 0.05 was considered statistically significant. Quantitative data are presented as mean values ± SEM in % of totals. Due to variabilities in isolation and analysis, the number (n) of treatments was not always identical.
Results
▼
Control conditions
The total content of 1 × 10 8 platelets was 747 ± 215 ng serotonin (n = 17), 255 ± 49 pg NGF (n = 9) and 418 ± 100 pg BDNF (n = 15) 
Eff ects of drugs on serotonin release from rat platelets
All 3 antidepressants (citalopram, sertraline or paroxetine) increased the serotonin release under calcium-free conditions after 10 and 60 min ( • ▶ Table 2A ). The anti-infl ammatory drug indomethacin increased the serotonin release under calciumfree conditions only after 60 min. Ibuprofen did not alter the serotonin release under calcium-free conditions ( • ▶ Table 2A ).
Under calcium conditions ibuprofen and paroxetine signifi cantly released more serotonin after 10 min, while all other treatments with calcium did not increase the serotonin release from platelets either after 10 or 60 min ( • ▶ Table 2B ).
Eff ects of drugs on NGF release from rat platelets
Under calcium-free conditions only sertraline reduced the NGF release from platelets after 10 min ( • ▶ Table 3A ). NGF release was reduced under calcium conditions by ibuprofen, paroxetine and sertraline after 10 min, but not after 60 min ( • ▶ Table 3B ). Citalopram and indomethacin did not aff ect NGF release ( • ▶ Table 3A , B ).
Eff ects of drugs on BDNF release from rat platelets
No eff ect on BDNF release was seen under calcium-free conditions with all tested drugs ( • ▶ reduced by the anti-infl ammatory drug ibuprofen after 10 and 60 min ( • ▶ Table 4B ).
Discussion ▼ Our present study shows that anti-infl ammatory drugs and antidepressants infl uence release of NGF and BDNF from rat platelets in a calcium-sensitive way. Serotonin was used as a positive control.
Platelets and storage of molecules
Platelets have 3 types of secretory granules: dense bodies, alpha granules and lysosomes. Dense bodies contain ATP, ADP, serotonin and calcium. Alpha granules contain diff erent growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor-beta 1 (TGF-1β), platelet factor 4 as well as other proteins necessary for functional activity (e. g., fi brinogen, von Willebrand factor, factors V and VIII). Lysosomes contain acid hydrolases [ 17 ] . The granules content is secreted following activation by a wide variety of stimuli, such as ADP and thrombin. Thrombin is a very strong stimulus that has been widely used to study platelet secretion. Thrombin causes exocytosis of dense bodies and degranulation of alpha granules, while thrombin induces alpha granule secretion at a lower concentration than the secretion of dense bodies. Furthermore, it was shown that the secretion induced by diff erent stimuli requires the formation of arachidonic acid metabolites or depends on temperature or calcium concentration [ 17 ] . Also, it has been shown that NGF is stored in dense bodies, while BDNF is stored in alpha granules [ 17 , 20 ] .
Role of calcium on platelet release
Calcium regulates various cellular processes, including cellular activation and degranulation in platelets [ 21 ] . Elevation in calcium concentrations derive from either the release of intragranular stores or extracellular calcium, which plays an important role in platelet activation and secretion. The calcium ionophore A23187 causes platelet secretion in a similar manner as thrombin and high concentrations of calcium and thrombin lead to an immediate release of diverse growth factors including PDGF and TGF-1β [ 22 , 23 ] . In human and rat platelets a weak inhibiting eff ect of calcium on serotonin reuptake has been shown [ 24 ] . In our study we used 2 mM calcium, which is a well established extracellular concentration. We show that calcium had slight but not signifi cant eff ects on serotonin release and a pronounced strong eff ect on BDNF release from platelets after 10 and 60 min.
Serotonin release from platelets as a positive control
Already in the 1960s Bartholini and Pletscher [ 25 ] had shown that platelets incubated in physiological medium (e. g., Tyrode buff er) release only a small amount of serotonin, which is induced by thrombin within a few minutes. The vesicular monoamine transporter inhibitor reserpine induces the release of serotonin from platelets and inhibits the reuptake of serotonin in dense granules [ 26 ] . Several antidepressants directly increase the release of serotonin and inhibit the reuptake of serotonin into dense granules [ 27 , 28 ] . In addition, SSRIs induce depletion of platelet serotonin levels and reduce platelet activation [ 29 , 30 ] . Our data are in full agreement, showing low secretion of serotonin and that SSRIs inhibit the reuptake of serotonin from platelets. NSAIDs are COX inhibitors, which suppress prostaglandin synthesis from arachidonic acid and suppress platelet aggregation 
(4) ns
Rat platelets were isolated from whole blood. Anti-infl ammatory drugs or antidepressants without ( A ) or with ( B ) Ca 2+ were added and platelets were incubated at 37 °C for 10 or 60 min. Supernatants were collected and serotonin was analyzed by HPLC-EC. Values are given as mean ± SEM % of total control. The number of analyzed samples is given in parenthesis. Statistical analysis was performed by one-way ANOVA with a Fisher LSD posthoc test. *p < 0.05; **p < 0.01; ***p < 0.001; ns , not signifi cant [ 31 ] . COX inhibitors do not inhibit serotonin reuptake, but they restrain the stimulation by cytokines. Inhibition of pro-infl ammatory cytokines leads to a down-regulation of indoleamine 2,3-dioxygenase (IDO). IDO is the rate-limiting enzyme in the tryptophan-kynurenine pathway and triggers the synthesis of serotonin to kynurenine [ 32 ] . Thereby COX inhibitors may directly infl uence the serotonin metabolism and sero tonin availability. In the present study we show that NSAIDs did not increase serotonin release after 10 min, but indomethacin enhanced the release after 60 min. It seems likely that the eff ects of NSAIDs are time-, dose-and drug-specifi c. Previously it had already been shown that NSAIDs inhibit the secretion only at very low agonist concentrations [ 17 ] .
NGF release from platelets and eff ects of drugs
The function of NGF in blood is unclear and little is known about NGF in platelets. A recent study has shown that NGF serum concentrations were not altered by antidepressant treatment and that serum concentrations were not related to the antidepressant type [ 12 ] . Our data show, for the fi rst time, that NGF is markedly released from rat platelets. This was an interesting novel observation showing that almost all (90 %) of NGF is spontaneously released from platelets. In the brain, release of NGF is highly regulated and infl uenced by neuronal activity [ 33 ] . NGF is generated from a precursor molecule (proNGF), which undergoes processing to generate mature NGF [ 33 ] . The NGF precursor and proteases are stored in neuronal compartments from which they are simultaneously released after neuronal stimulation [ 34 ] . In neurons, a basal constitutive secretion of NGF can be partially blocked by, e. g., lowering the incubation temperature [ 33 ] . In platelets, NGF is contained in dense bodies and mainly the whole granular content is spontaneous released within minutes. However, serotonin release accounts only for about 10-15 % and thus it seems likely that NGF and serotonin release are differentially regulated, because markedly more NGF is released than serotonin. This fi nding points to uptake mechanisms, degradation or binding to extracellular molecules or to platelet membranes. Our data show for the fi rst time that sertraline spontaneously reduced release of NGF, but only after 10 min under calcium-free or calcium-containing conditions. It is fully unclear why the release was not altered after 60 min. This may indeed indicate that the eff ect of sertraline is only a fast and transient one and that NGF is further released with time. Similarly, ibuprofen and paroxetine also reduced NGF release but only when calcium was present. Thus, we conclude that the release of NGF from platelets is uncontrolled and can only be partly and transiently inhibited by some specifi c drugs. The mechanism of such a fast release needs to be further explored in detail.
BDNF release from platelets and eff ects of drugs
Stress activates several neurotransmitters and the endocrine system including the hypothalamic-pituitary-adrenal (HPA) axis as a key hormonal component [ 35 ] . BDNF signaling plays a critical role in the regulation of the HPA axis suggesting an endocrine role for BDNF [ 36 , 37 ] . In depression the HPA axis is disturbed and BDNF serum levels are decreased. However, the function of BDNF in the blood is still poorly understood and confl icting results about BDNF serum, plasma and platelet BDNF levels have emerged. In serum of antidepressant-naïve or -free depressed patients decreased BDNF concentrations have been observed. The serum BDNF levels increased after antidepressant treatment [ 14 , 38 , 39 ] . It has been suggested that BDNF released from platelets directly correlate to serum BDNF levels. Indeed, platelet BDNF is reduced in depressed patients and serum BDNF levels are enhanced after stimulation on platelets by antidepressant treatment [ 10 , 15 ] . Furthermore, Serra-Millas et al. [ 40 ] reported high platelet BDNF and low plasma BDNF levels in healthy controls. Recently it has been reported that antidepressants induce a marked BDNF release from rat platelets in a time-and dosedependent manner [ 15 ] . Contrary, it has been shown that collagen induces platelet activation and aggregation is inhibited by antidepressants by inhibiting granule secretion from platelets [ 28 ] . Another study showed that aspirin (a non-specifi c COXinhibitor) reduces the release of BDNF from platelets [ 41 ] , while a recent study reported that aspirin did not aff ect BDNF release [ 42 ] . Taken together, there is a strong controversy on showing release of BDNF from platelets. It seems likely that the type of isolation of platelets may markedly aff ect the results, such as, e. g., using EDTA/citrate tubes, puff ers with or without calcium, pH during isolation and use of diverse inhibitors. Our data are in clear contrast to those of Watanabe et al. [ 15 ] showing that all antidepressants did not aff ect the release of BDNF under calcium-free conditions. Unfortunately, Watanabe et al. [ 15 ] did not provide detailed information on platelet isolation, thus diff erences in platelet preparation may account for the diff erences to our study. Furthermore, they did not provide raw values, making it diffi cult to directly compare our data. Our data also show that only ibuprofen aff ected BDNF release but only when calcium was present. This goes in line with the work of Fujimura et al. [ 43 ] , who observed a rapid release of BDNF from human platelets with the calcium ionophore A23187. We suggest that ibuprofen reduced BDNF release possibly involving COX inhibition and calcium-mediated release from alpha granules.
Conclusion
▼
In our present study we use platelets from rats, which allows us to study cellular mechanisms in a simple homogenous and reproducible cell type. Our study is the fi rst to investigate the infl uence of 3 antidepressants (citalopram, sertraline, paroxetine) and 2 non-steroidal anti-infl ammatory drugs (ibuprofen, indomethacin) with or without calcium on NGF and BDNF release and serotonin as a control from rat platelets. The infl uence of antidepressants and anti-infl ammatory drugs on NGF and BDNF release diff ers depending on the drug type, dose and maybe on the incubation period. It is concluded that the release of the 2 growth factors NGF and BDNF contributes to blood levels, which may indicate a role in platelet-derived function, including vascular mechanisms. Further studies should clarify the mechanisms of NGF and BDNF release also in human platelets.
